Evidence suggests that the incretin effect is blunted in T2DM patients, most likely as a consequence of the diabetic state [36,37,38,39], and the disruption of the insulinotropic effect of incretins particularly occurs in glucose homeostatic dysregulation. The gene discussed is GCG; the disease is type 2 diabetes mellitus.